Blood Lead Levels |
|
|
Clinical Trial: A Study in People with Abnormal Fat Levels in the Blood
This study is currently recruiting patients.
|
Purpose
The purposes of this study are to determine:
- The safety of the study medication and any side effects that might be associated with it;
- Whether the study medication can help patients with low levels of “good” cholesterol (HDL-C) and high blood fats or triglycerides (TG);
- How much of the study medication should be given to patients;
- How the study medication compares to fenofibrate (Lofibra), a drug used for people with low levels of HDL-C and high levels of TG.
| Condition | Intervention | Phase |
|---|---|---|
| Dyslipidemia | Drug: Oral medication taken by people with abnormal fat levels in the blood | Phase II |
MedlinePlus related topics: Metabolic Disorders
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: PPAR Alpha: A Phase 2 Dose-Finding and Safety Study for Atherogenic Dyslipidemia
Expected Total Enrollment: 300
Study start: June 2005; Expected completion: July 2006
Eligibility
Inclusion Criteria:
- Men and women between 18 and 80 years of age
- People with abnormal fat levels in the blood (low HDL, high TG)
Exclusion Criteria:
Location and Contact Information
Florida
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Longwood, Florida, United States; Recruiting
More Information
Record last reviewed: June 2005
Last Updated: June 30, 2005
Record first received: June 29, 2005
ClinicalTrials.gov Identifier: NCT00116519
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-07-05

Not Signed In -


